FUJIFILM Holdings America Corporation's Commitment during the Novel Coronavirus (COVID-19) Pandemic
With the collective goal of enhancing society through innovation, the Fujifilm family is committed to leveraging its resources, talent and technologies to support global efforts to counter the COVID-19 pandemic.
Our sincere gratitude and respect go out to all the healthcare professionals that are working to save lives and aid in the prevention of COVID-19. To help improve patient outcomes throughout the care spectrum, Fujifilm applauds clinicians that are on the front lines treating patients on a daily basis.
During this time, our number one priority remains the health and safety of our customers, workforce and the broader community. In response to the pandemic, we’ve adapted our business practices in order to safeguard our staff, as well as continue to serve our customers, many of which are powering critical operations in the fields of healthcare, technology and media.
As a total healthcare company involved in Prevention, Diagnosis and Treatment, we are committed to supporting the brave clinicians caring for COVID-19 patients with our technologies.
To aid in prevention, we stand ready to support the manufacture of vaccines with world-class biologics production facilities and technical expertise. Of note, FUJIFILM Diosynth Biotechnologies has been selected to manufacture Novavax' COVID-19 vaccine candidate at its North Carolina facilities. In addition, it has reserved manufacturing capacity at its Flexible Biomanufacturing Facility in Texas to expand production of a COVID-19 vaccine candidate as part of Operation Warp Speed. FUJIFILM Diosynth Biotechnologies is also leveraging its manufacturing and technical expertise to team up with the COVID-19 Therapeutics Accelerator to reserve manufacturing capacity and provide technical expertise to deliver future COVID-19 therapies.
In the field of diagnosis, our efforts include the provision of a gene-testing research tool which lessens the time required for polymerase chain reaction (PCR) testing*. Our point-of-care imaging equipment such as ultrasound and mobile X-ray systems are playing a vital role in the clinical care of patients with COVID-19. With a heightened awareness of respiratory symptoms amid the COVID-19 outbreak, there is an increased focus on pulmonary diagnostic exams for which Fujifilm offers a broad range of endoscopes for pulmonary indications.
Our work in the treatment field includes clinical trials in Japan and the U.S. to evaluate the safety and efficacy of our influenza antiviral drug Avigan® Tablet for patients with COVID-19. Additionally. FUJIFILM Group life science companies are providing critical raw materials necessary for the development of potential COVID-19 vaccines and therapies.
Collaborative care happens when clinicians across the enterprise can instantly access the latest patient data, clinical statements, and report histories—and communicate over shared exam states with their colleagues. Our Enterprise Imaging solutions are affording clinicians the ability to visualize and monitor patients across their entire care pathway, enabling a level of collaboration that this health crisis requires.
In addition to our healthcare capabilities, Fujifilm is involved in a number of manufacturing businesses that are supporting essential and critical operations at this time including graphic plates, ink and other supplies for newspapers and media services; packaging and supplies for Healthcare organizations; and supplies for industry X-ray film and imaging plates for essential infrastructure.
Through collaboration, technology and our collective expertise, we will continue to work towards improving human health and helping bring the pandemic to an end.
* Available only in Japan and not available for sale in other country/regions
Our number one priority is the safety of our customers, workforce and the broader community.
See key messages below from Tetsuya Iwasaki, President of FUJIFILM Holdings America Corporation, and President & CEO, FUJIFILM North America Corporation, or click here to read the message in its entirety.
Our Commitment to our Customers:
As this is a rapidly evolving situation, we have adjusted our business practices in order to safeguard the health and safety or our workers, customers and the community, and to comply with various recently ordered state and local orders. We are following governmental orders in the locations where we operate and we have frequently communicated supply chain and distribution updates to our partners.
We are also taking proactive measures to ensure the health and safety of our staff and customers. As such, we have temporarily closed the Wonder Photo Shop in New York City and the camera repair drop-off and pick-up in Edison, New Jersey. During this time, we are still committed to providing exceptional service to our customers. For support, customers are still welcome to contact us.
Our Commitment to our Workforce:
As a company, we are doing our part to enhance society, as well as taking precautions for our workforce. To respond to emerging events tied to COVID-19, Fujifilm has directed specific procedures in order to maintain a safe workforce. Until further notice, we have enacted a work-from-home policy for all non-essential personnel, social distancing and split shifts for essential workers on-site, extensive cleaning procedures at our sites, encouraging workers to follow good hygiene practices based on the CDC guidelines, as well as restricting travel, meetings, events and visitors, to comply with social distancing requirements.
Our Commitment to the Community:
Overall, FUJIFILM North America Corporation is involved in a number of manufacturing businesses that are supporting essential and critical operations at this time including graphic plates, ink and other supplies for newspapers and media services; packaging and supplies for Healthcare organizations; and supplies for industry X-ray film and imaging plates for essential infrastructure. Fujifilm is committed to supporting these businesses during this critical time.
In addition, several of our sister Fujifilm companies in the United States are engaged in healthcare and life science products and services; this includes diagnostic imaging equipment, which is critical to the care process of COVID-19 patients; the manufacture and production of cell culture media, which are raw materials for therapies, vaccines and diagnostics; as well as providing contract development and manufacturing services to various bio-pharma companies.
Fujifilm's Global Actions Against COVID-19
On April 9, 2020, FUJIFILM Corporation announced the initiation of a phase II clinical trial to evaluate the safety and efficacy of its influenza antiviral drug “Avigan® Tablet*” (generic name: favipiravir) for patients with COVID-19 in the United States. See details in the press release here.
* Avigan Tablet is not FDA approved in the United States.
Interview with Dr. Mangala Narasimhan on Responding to COVID-19 in New York.
Fujifilm Sonosite Chief Medical Officer Diku Mandavia, MD. interviews Dr. Enrico Storti on COVID-19
Fujifilm Takes Action and Coordinates Efforts to Support Healthcare Needs for Clinical Staff Engaged in Phase II Clinical Trials
At Fujifilm, our dedication to science and innovation has never been more important than it is today. We are collaborating across the globe and working together and finding ways to fight COVID-19 by leveraging our talents, experience and resources. Read More
"Never Stop" Philosophy Guides FUJIFILM Dimatix, Inc. in Helping Produce Face Shields for COVID-19 Response
FUJIFILM Dimatix is producing and donating 20,000 face shields for COVID-19 first responders at Dartmouth-Hitchcock Medical Center, a local health system in Lebanon, New Hampshire, U.S.A. It's a testament to community spirit and the desire to help in a time of need. Read More
Pictured Employees from Left to Right: Ellen Raymond and Erik Bergeron
Left to Right: Fred Amidon, Ellen Raymond and Sean Murphy
Left to Right: Ellen Raymond and Sean Murphy
Left to Right: Ellen Raymond and Sean Murphy